Vijay Chaitanya Ganta1, Min Choi1, Anna Kutateladze1, Brian H Annex2. 1. From the Cardiovascular Research Center (V.C.G., M.C., B.H.A.), Department of Biology (A.K.), and Department of Cardiovascular Medicine, University of Virginia, Charlottesville (B.H.A.). 2. From the Cardiovascular Research Center (V.C.G., M.C., B.H.A.), Department of Biology (A.K.), and Department of Cardiovascular Medicine, University of Virginia, Charlottesville (B.H.A.). annex@virginia.edu.
Abstract
RATIONALE: Atherosclerotic-arterial occlusions decrease tissue perfusion causing ischemia to lower limbs in patients with peripheral arterial disease (PAD). Ischemia in muscle induces an angiogenic response, but the magnitude of this response is frequently inadequate to meet tissue perfusion requirements. Alternate splicing in the exon-8 of vascular endothelial growth factor (VEGF)-A results in production of proangiogenic VEGFxxxa isoforms (VEGF165a, 165 for the 165 amino acid product) and antiangiogenic VEGFxxxb (VEGF165b) isoforms. OBJECTIVE: The antiangiogenic VEGFxxxb isoforms are thought to antagonize VEGFxxxa isoforms and decrease activation of VEGF receptor-2 (VEGFR2), hereunto considered the dominant receptor in postnatal angiogenesis in PAD. Our data will show that VEGF165b inhibits VEGFR1 signal transducer and activator of transcription (STAT)-3 signaling to decrease angiogenesis in human and experimental PAD. METHODS AND RESULTS: In human PAD versus control muscle biopsies, VEGF165b: (1) is elevated, (2) is bound higher (versus VEGF165a) to VEGFR1 not VEGFR2, and (3) levels correlated with decreased VEGFR1, not VEGFR2, activation. In experimental PAD, delivery of an isoform-specific monoclonal antibody to VEGF165b versus control antibody enhanced perfusion in animal model of severe PAD (Balb/c strain) without activating VEGFR2 signaling but with increased VEGFR1 activation. Receptor pull-down experiments demonstrate that VEGF165b inhibition versus control increased VEGFR1-STAT3 binding and STAT3 activation, independent of Janus-activated kinase-1)/Janus-activated kinase-2. Using VEGFR1+/- mice that could not increase VEGFR1 after ischemia, we confirm that VEGF165b decreases VEGFR1-STAT3 signaling to decrease perfusion. CONCLUSIONS: Our results indicate that VEGF165b prevents activation of VEGFR1-STAT3 signaling by VEGF165a and hence inhibits angiogenesis and perfusion recovery in PAD muscle.
RATIONALE: Atherosclerotic-arterial occlusions decrease tissue perfusion causing ischemia to lower limbs in patients with peripheral arterial disease (PAD). Ischemia in muscle induces an angiogenic response, but the magnitude of this response is frequently inadequate to meet tissue perfusion requirements. Alternate splicing in the exon-8 of vascular endothelial growth factor (VEGF)-A results in production of proangiogenic VEGFxxxa isoforms (VEGF165a, 165 for the 165 amino acid product) and antiangiogenic VEGFxxxb (VEGF165b) isoforms. OBJECTIVE: The antiangiogenic VEGFxxxb isoforms are thought to antagonize VEGFxxxa isoforms and decrease activation of VEGF receptor-2 (VEGFR2), hereunto considered the dominant receptor in postnatal angiogenesis in PAD. Our data will show that VEGF165b inhibits VEGFR1 signal transducer and activator of transcription (STAT)-3 signaling to decrease angiogenesis in human and experimental PAD. METHODS AND RESULTS: In human PAD versus control muscle biopsies, VEGF165b: (1) is elevated, (2) is bound higher (versus VEGF165a) to VEGFR1 not VEGFR2, and (3) levels correlated with decreased VEGFR1, not VEGFR2, activation. In experimental PAD, delivery of an isoform-specific monoclonal antibody to VEGF165b versus control antibody enhanced perfusion in animal model of severe PAD (Balb/c strain) without activating VEGFR2 signaling but with increased VEGFR1 activation. Receptor pull-down experiments demonstrate that VEGF165b inhibition versus control increased VEGFR1-STAT3 binding and STAT3 activation, independent of Janus-activated kinase-1)/Janus-activated kinase-2. Using VEGFR1+/- mice that could not increase VEGFR1 after ischemia, we confirm that VEGF165b decreases VEGFR1-STAT3 signaling to decrease perfusion. CONCLUSIONS: Our results indicate that VEGF165b prevents activation of VEGFR1-STAT3 signaling by VEGF165a and hence inhibits angiogenesis and perfusion recovery in PAD muscle.
Authors: W Schuyler Jones; Brian D Duscha; Jennifer L Robbins; Natasha N Duggan; Judith G Regensteiner; William E Kraus; William R Hiatt; Ayotunde O Dokun; Brian H Annex Journal: Vasc Med Date: 2012-03-08 Impact factor: 3.239
Authors: Clément d'Audigier; Benoit Gautier; Alexis Yon; Jean-Meidi Alili; Coralie L Guérin; Solène M Evrard; Anne Godier; Skerdi Haviari; Marie Reille-Serroussi; Florent Huguenot; Blandine Dizier; Nicolas Inguimbert; Delphine Borgel; Ivan Bièche; Catherine Boisson-Vidal; Carmen Roncal; Peter Carmeliet; Michel Vidal; Pascale Gaussem; David M Smadja Journal: Angiogenesis Date: 2014-01-14 Impact factor: 9.596
Authors: Sang Hun Lee; Kyeung Bin Lee; Jun Hee Lee; Songhwa Kang; Hwi Gon Kim; Takayuki Asahara; Sang Mo Kwon Journal: Stem Cells Date: 2015-05 Impact factor: 6.277
Authors: Jeanette Woolard; Wen-Ying Wang; Heather S Bevan; Yan Qiu; Lucia Morbidelli; Rowan O Pritchard-Jones; Tai-Gen Cui; Marto Sugiono; Elizabeth Waine; Rachel Perrin; Rebecca Foster; Jonathon Digby-Bell; Jacqueline D Shields; Cheryl E Whittles; Rosey E Mushens; David A Gillatt; Marina Ziche; Steven J Harper; David O Bates Journal: Cancer Res Date: 2004-11-01 Impact factor: 12.701
Authors: Sanjay Rajagopalan; Emile R Mohler; Robert J Lederman; Farrell O Mendelsohn; Jorge F Saucedo; Corey K Goldman; John Blebea; Jennifer Macko; Paul D Kessler; Henrik S Rasmussen; Brian H Annex Journal: Circulation Date: 2003-09-22 Impact factor: 29.690
Authors: Yared Tekabe; Qing Li; Geping Zhang; Jordan Johnson; Ann Marie Schmidt; Marina Backer; Joseph Backer; Lynne L Johnson Journal: Mol Imaging Biol Date: 2018-12 Impact factor: 3.488
Authors: Vijay Chaitanya Ganta; Min Hyub Choi; Anna Kutateladze; Todd E Fox; Charles R Farber; Brian H Annex Journal: Circulation Date: 2017-03-29 Impact factor: 29.690
Authors: Eva Latorre; Luke C Pilling; Benjamin P Lee; Stefania Bandinelli; David Melzer; Luigi Ferrucci; Lorna W Harries Journal: Clin Sci (Lond) Date: 2018-02-02 Impact factor: 6.124